Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients (CHIRP)

This is an interventional treatment trial for High-risk Prostate Cancer focused on measuring high risk prostate cancer, hypofractionated radiation treatment, higher biological doses, acceptable rectal toxicity, Radiation Treatment Read More

Inclusion Criteria:

• Patient is 18 years of age or older
• Patient has histologically proven adenocarcinoma of prostate gland by needle core samples or TURP with assigned Gleason score. Prostate biopsy performed within 180 days of enrollment (date of consent).
• Patient has high-risk prostate cancer (stage T3 or T4) and/or PSA greater than or equal to 20 ng/ml and/or Gleason score 8 to 10
• No clinical or radiological evidence of nodal or distant metastasis(es).
• In the opinion of the treating oncologist, patient is fit to undergo radical external beam radiotherapy to the prostate. Patients are accessible for treatment and follow up.
• Patient does not have history of inflammatory bowel disease, anal stenosis, colorectal surgery, or repeated endoscopic examinations/interventions related to anorectal diseases.
• No history of prostatectomy, transurethral resection of prostate on more than one occasion or previous pelvic radiotherapy.
• No history of androgen suppression for greater than or equal to 6 months and patient is willing for androgen suppression treatment as per standard or at physician's discretion.
• No previous malignancy within last five years except BCC or SCC skin or highly curable malignancy where a prognosis for cure is > 80%.
• Patient signed informed consent.